{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:35:40Z","timestamp":1767792940823,"version":"3.49.0"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,11,22]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study characterised the use and perceptions of cannabis and vaping in people with cystic fibrosis (CF) and CF transmembrane conductance regulator (CFTR)-related disorder followed by a large Canadian adult CF clinic. It also aimed to assess whether cannabis legalisation in Canada affected perceived benefits and harms, and whether media attention regarding e-cigarette or vaping product use-associated lung injury (EVALI) affected perceptions of vaping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An electronic questionnaire was emailed to all clinic patients on 23 April 2021, and remained open until 28 October 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>110 individuals completed the questionnaire, of whom 43% identified as a current user of cannabis. As a result of legalisation, 14% of respondents reported change in their perceptions of cannabis, primarily related to decreased stigma and increased awareness of medical indications and potential side effects. Cannabis was reported as being used medically for 85% of current users, with stress, insomnia\/lack of sleep, and anxiety being the most common symptoms treated; the majority reported it to be somewhat or very effective to manage symptoms. Overall, 33% of respondents had tried vaping, but only 7% considered themselves current vapers. For 45% of respondents, the 2019 EVALI epidemic was reported to have changed perceptions of potential short-term and long-term effects associated with vaping, with increased awareness of potential harms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cannabis use was common, with a reported increase since its legalisation in this population. EVALI media attention was reported to increase awareness for potential harms associated with vaping. CF healthcare providers are well positioned to provide education and support so patients can make informed decisions about cannabis use and vaping.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002715","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T09:30:17Z","timestamp":1766655017000},"page":"e002715","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the use and perceptions of cannabis and vaping post-cannabis legalisation in people with cystic fibrosis and CFTR-related disorder: survey results from a large Canadian adult cystic fibrosis clinic"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-0614","authenticated-orcid":false,"given":"Renee","family":"Dagenais","sequence":"first","affiliation":[{"name":"Adult Cystic Fibrosis Clinic, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"},{"name":"Department of Pharmacy, St. Paul's Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2124-6525","authenticated-orcid":false,"given":"Emma","family":"Karlsen","sequence":"additional","affiliation":[{"name":"The University of British Columbia Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2223-4182","authenticated-orcid":false,"given":"Kathleen","family":"Lee","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Clinic, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley Stuart","family":"Quon","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Clinic, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"},{"name":"The University of British Columbia Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"2026010701515990000_12.1.e002715.1","unstructured":"Government of Canada . Consolidated federal laws of Canada, Cannabis Act. 2023. Available: https:\/\/laws-lois.justice.gc.ca\/eng\/acts\/c-24.5\/ [Accessed 31 Dec 2022]."},{"key":"2026010701515990000_12.1.e002715.2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.healthpol.2018.01.009","article-title":"The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018","volume":"122","author":"Cox","year":"2018","journal-title":"Health Policy"},{"key":"2026010701515990000_12.1.e002715.3","unstructured":"Government of Canada . For health care professionals: cannabis and cannabinoids. 2018. Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/information-medical-practitioners\/information-health-care-professionals-cannabis-cannabinoids.html [Accessed 31 Dec 2022]."},{"key":"2026010701515990000_12.1.e002715.4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.17269\/s41997-018-00173-1","article-title":"Potential harms from legalization of recreational cannabis use in Canada","volume":"110","author":"Windle","year":"2019","journal-title":"Can J Public Health"},{"key":"2026010701515990000_12.1.e002715.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.3.221"},{"key":"2026010701515990000_12.1.e002715.6","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201212-127FR"},{"key":"2026010701515990000_12.1.e002715.7","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.293","article-title":"Marijuana \u201cbong\u201d pseudomonas lung infection: a detrimental recreational experience","volume":"6","author":"Kumar","year":"2018","journal-title":"Respirol Case Rep"},{"key":"2026010701515990000_12.1.e002715.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-016-0119-9","article-title":"Medical cannabis use in Canada: vapourization and modes of delivery","volume":"13","author":"Shiplo","year":"2016","journal-title":"Harm Reduct J"},{"key":"2026010701515990000_12.1.e002715.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.007667"},{"key":"2026010701515990000_12.1.e002715.10","unstructured":"Centers for Disease Control and Prevention . Smoking and tobacco use; electronic cigarettes. 2021. Available: https:\/\/www.cdc.gov\/tobacco\/basic_information\/e-cigarettes\/severe-lung-disease.html [Accessed 31 Dec 2022]."},{"key":"2026010701515990000_12.1.e002715.11","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1056\/NEJMc1913069","article-title":"Pathology of Vaping-Associated Lung Injury","volume":"381","author":"Butt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010701515990000_12.1.e002715.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.09.002"},{"key":"2026010701515990000_12.1.e002715.13","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(07)60350-6","article-title":"383 Use of non-prescribed drugs in adult CF patients","volume":"6","author":"Burhan","year":"2007","journal-title":"J Cyst Fibros"},{"key":"2026010701515990000_12.1.e002715.14","unstructured":"Lee K , MacDiarmid P , Shalansky S . The use of self-administered medicinal cannabis for CF symptom management: patient-reported experiences. Salt Lake City Utah, 2013."},{"key":"2026010701515990000_12.1.e002715.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(87)80090-2"},{"key":"2026010701515990000_12.1.e002715.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12906-020-03116-x","article-title":"Use of medical marijuana in cystic fibrosis patients","volume":"20","author":"Stephen","year":"2020","journal-title":"BMC Complement Med Ther"},{"key":"2026010701515990000_12.1.e002715.17","unstructured":"Gilmore D , Hooper C , Nemastil C , et al . Effects of self-reported marijuana use on adherence and mental health disease in cystic fibrosis. Denver, CO, 2020."},{"key":"2026010701515990000_12.1.e002715.18","unstructured":"Chowdhury J , Stephen M . Complementary and alternative medicine in cystic fibrosis patients. Indianapolis, IN, 2017."},{"key":"2026010701515990000_12.1.e002715.19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.101.2.250"},{"key":"2026010701515990000_12.1.e002715.20","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2013.805976"},{"key":"2026010701515990000_12.1.e002715.21","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7517-2-18","article-title":"Survey of Australians using cannabis for medical purposes","volume":"2","author":"Swift","year":"2005","journal-title":"Harm Reduct J"},{"key":"2026010701515990000_12.1.e002715.22","first-page":"17","article-title":"Marijuana Use and Perceptions of Risk and Harm: A Survey among Canadians in 2016","volume":"13","author":"Spackman","year":"2017","journal-title":"Healthc Policy"},{"key":"2026010701515990000_12.1.e002715.23","unstructured":"R Core Team . R: a language and environment for statistical computing. Vienna, Austria, 2020. Available: https:\/\/www.R-project.org\/"},{"key":"2026010701515990000_12.1.e002715.24","unstructured":"Posit team . RStudio: integrated development environment for R. PBC, Boston, MA Posit Software; 2024. Available: http:\/\/www.posit.co\/"},{"key":"2026010701515990000_12.1.e002715.25","unstructured":"BC Cannabis Secretariat and BC Stats . Cannabis in British Columbia: results from the 2021 BC cannabis use survey. BC Ministry of Public Safery and Solicitor General; 2022. Available: https:\/\/www2.gov.bc.ca\/assets\/gov\/public-safety-and-emergency-services\/public-safety\/cannabis\/2021_bc_cannabis_use_survey_report_final.pdf"},{"key":"2026010701515990000_12.1.e002715.26","unstructured":"Government of Canada . Canadian cannabis survey 2021: summary. 2021. Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/research-data\/canadian-cannabis-survey-2021-summary.html [Accessed 31 Dec 2022]."},{"key":"2026010701515990000_12.1.e002715.27","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00213-021-06047-8","article-title":"Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada","volume":"239","author":"Leung","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"2026010701515990000_12.1.e002715.28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcf.2022.08.006","article-title":"Prevalence of unmet pain and symptom management needs in adults with cystic fibrosis","volume":"22","author":"Dubin","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026010701515990000_12.1.e002715.29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051154","article-title":"Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review","volume":"11","author":"Lopera","year":"2022","journal-title":"J Clin Med"},{"key":"2026010701515990000_12.1.e002715.30","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060458","article-title":"CFTR Modulators: Does One Dose Fit All?","volume":"11","author":"van der Meer","year":"2021","journal-title":"J Pers Med"},{"key":"2026010701515990000_12.1.e002715.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103716"},{"key":"2026010701515990000_12.1.e002715.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.08.976","article-title":"Assessment of vaping practices in patients with cystic fibrosis","volume":"158","author":"Rhoads","year":"2020","journal-title":"Chest"},{"key":"2026010701515990000_12.1.e002715.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106419"},{"key":"2026010701515990000_12.1.e002715.34","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntac088"},{"key":"2026010701515990000_12.1.e002715.35","unstructured":"Kim M , Baumlin N , Dennis J , et al . Never-smokers develop mucosal inflammation and CFTR dysfunction upon vaping nicotine-free e-liquid for one week. San Diego, CA, 2018."},{"key":"2026010701515990000_12.1.e002715.36","unstructured":"Aller Paredes S , Aguiar C , Guerrero A , et al . E-cigarette vaping impairs electrolyte transport over the apical nasal mucosa. Washington, DC; 2017."},{"key":"2026010701515990000_12.1.e002715.37","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/ppul.25563","article-title":"A clinician survey of use assessment, documentation, and education about cannabis in persons with cystic fibrosis","volume":"56","author":"Muirhead","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026010701515990000_12.1.e002715.38","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ppul.26241","article-title":"Clearing up the smoke: Physical and mental health considerations regarding cannabis use in adolescents with cystic fibrosis","volume":"58","author":"Ince","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026010701515990000_12.1.e002715.39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:53:41Z","timestamp":1767779621000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,25]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjresp-2024-002715"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002715","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}